HRT FINANCIAL LP sold $6K of TNON

Tenon Medical Inc. (NASDAQ: TNON) shares surged 53.64% after repaying $5.16M in convertible notes, reducing debt risk. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin. Despite strong growth, TNON faces financial challenges, including a $4.05M net loss and negative equity. Traders are monitoring the stock due to its volatility and recent catalysts, such as FDA clearance and increased surgical volume.

Tenon Medical Inc. (TNON) shares rose 55.66% after repaying $5.16M in convertible notes early. The company reported Q2 2026 revenue of $1.3M, up 127% YoY, with a 64% gross margin, but a net loss of $4.05M. TNON's stock is highly volatile, driven by news and liquidity rather than fundamentals.

Tenon Medical (TNON) shares rose 54.53% in premarket trading after repaying $5.16M in debt, avoiding share dilution. The company also completed a 1-for-35 reverse split and regained Nasdaq compliance. Q2 revenue grew 127% YoY to $1.28M, with a 64% gross margin, though net loss was $4.1M.

Tenon Medical Inc. (TNON) stock surged 56.04% on September 11, 2026, following the company's repayment of $5.16M in convertible notes, removing a dilution risk. Q2 revenue grew 127% YoY to $1.3M, with a 64% gross margin, but the company remains unprofitable. TNON regained Nasdaq compliance and reported record surgical case volume.

Tenon Medical Inc. (TNON) shares rose 55.66% after the company cleared $5.16M in debt ahead of schedule, improving its balance sheet. The stock has shown high volatility, with a recent surge from $2.44 to $5.30. TNON reported Q2 2026 revenue growth of 127% YoY to $1.3M, but remains unprofitable with a net loss of $4.1M. The company secured FDA clearance for a medical device and regained Nasdaq compliance, but faces liquidity challenges and potential future capital raises.

Tenon Medical (NASDAQ:TNON) reported Q2 2026 revenue of $1.3M, up 127% year over year, and gross profit of $0.8M with 64% gross margin. Net loss was $4.1M ($12.35/share). The company received FDA 510(k) clearance for an updated Catamaran SI Joint Fusion System, closed a $4.2M public offering, and completed a 1-for-35 reverse split.